Brief: Sino Biopharmaceutical Says Positive Results On Phase Iii Study Of Benmelstobart Injection
23/05/2024 16:22
May 23 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK :
* POSITIVE RESULTS ON PHASE III STUDY OF BENMELSTOBART
INJECTION
IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up